| Biomedicine |
|
|
|
|
| Infliximab treatment in two Chinese patients with psoriatic arthritis |
| Xi Xie, Jin-wei Chen, Fen Li, Jing Tian, Jie-sheng Gao, David Zhang |
| Department of Rheumatology, the Second Xiangya Hospital, Central South University, Changsha 410011, China; Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA |
|
|
|
Abstract Psoriatic arthritis (PsA) is a rheumatoid factor (RF)-seronegative systemic inflammatory disorder associated with psoriasis. Current treatment for PsA in China is still focused on disease modifying anti-rheumatic drugs (DMARDs). In this paper, we report two Chinese patients with active longstanding PsA treated with infliximab, a human-mouse chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α). The results show that infliximab acted quickly and effectively in relieving peripheral and axial symptoms and refractory skin lesions, even in recombinant human TNF-α receptor (rhTNFR)-resistant case. The take-home message from our cases is that infliximab is a useful therapeutic option for refractory PsA, especially when a patient has a combination of psoriasis and psoriatic arthritis. Further local evidence and experience must be accumulated in order to make anti-TNF-α therapy more accessible to PsA patients in China.
|
|
Received: 11 March 2010
Published: 05 October 2010
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
